Analytical Data
-
基因名
CLEC9A
- Application
-
别名
C-type lectin domain family 9 member A; CD370; CLEC9A; UNQ9341/PRO34046
-
种属
Human
-
表达系统
E. coli
-
标签
GST-tag at N-terminal
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
CLEC9A
-
表达区间
1-241aa
-
氨基酸序列
MHEEEIYTSLQWDSPAPDTYQKCLSSNKCSGACCLVMVISCVFCMGLLTASIFLGVKLLQVSTIAMQQQEKLIQQERALLNFTEWKRSCALQMKYCQAFMQNSLSSAHNSSPCPNNWIQNRESCYYVSEIWSIWHTSQENCLKEGSTLLQIESKEEMDFITGSLRKIKGSYDYWVGLSQDGHSGRWLWQDGSSPSPGLLPAERSQSANQVCGYVKSNSLLSSNCSTWKYFICEKYALRSSV
-
分子量
53.7 KDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CLEC9A, or C-type lectin domain family 9 member A, is a receptor primarily expressed on the surface of dendritic cells, which plays a crucial role in the immune system by recognizing and binding to various pathogens. Research into CLEC9A recombinant proteins has gained traction due to its potential applications in immunotherapy and vaccine development. The protein has been shown to facilitate the uptake of antigenic material and enhance T cell activation, making it an attractive target for designing innovative therapeutic strategies against cancers and infectious diseases. Researchers aim to manipulate CLEC9A’s ability to present antigens to stimulate the immune response, thereby improving the efficacy of vaccines. Moreover, the use of recombinant CLEC9A proteins could enable the development of targeted therapies that harness the body’s own immune system to fight diseases more effectively. As the understanding of CLEC9A's molecular mechanisms deepens, it paves the way for novel approaches to harness dendritic cell biology in the context of both vaccine design and cancer immunotherapy, underlining the importance of this receptor in enhancing immune responses. Overall, the study of CLEC9A recombinant proteins holds significant promise for advancing the field of immunology and developing next-generation therapeutic modalities that could address the limitations of current treatments.
